首页> 外文期刊>Diabetes >Cdkn2a/p16~(Ink4a) Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1α Pathway
【24h】

Cdkn2a/p16~(Ink4a) Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1α Pathway

机译:Cdkn2a / p16〜(Ink4a)通过PKA-CREB-PGC1α途径调节空腹诱导的肝糖异生

获取原文
获取原文并翻译 | 示例
           

摘要

Type 2 diabetes (T2D) is hallmarked by insulin resistance, impaired insulin secretion, and increased hepatic glucose production. The worldwide increasing prevalence of T2D calls for efforts to understand its patho-genesis in order to improve disease prevention and management. Recent genome-wide association studies have revealed strong associations between the CDKN2A/B locus and T2D risk. The CDKN2A/B locus contains genes encoding cell cycle inhibitors, including p16~(Ink4a), which have not yet been implicated in the control of hepatic glucose homeostasis. Here, we show that p16~(Ink4a) deficiency enhances fasting-induced hepatic glucose production in vivo by increasing the expression of key gluconeogenic genes. p16~(Ink4a) downregulation leads to an activation of PKA-CREB-PGC1α signaling through increased phosphorylation of PKA regulatory subunits. Taken together, these results provide evidence that p16~(Ink4a) controls fasting glucose homeostasis and could as such be involved in T2D development.
机译:2型糖尿病(T2D)的特征是胰岛素抵抗,胰岛素分泌受损和肝葡萄糖生成增加。 T2D在世界范围内的普遍流行要求人们努力了解其发病机理,以改善疾病的预防和管理。最近的全基因组关联研究表明,CDKN2A / B基因座与T2D风险之间存在强关联。 CDKN2A / B基因座包含编码细胞周期抑制剂的基因,包括p16〜(Ink4a),尚未涉及肝葡萄糖稳态的控制。在这里,我们显示p16〜(Ink4a)缺乏症通过增加关键糖异生基因的表达来增强体内空腹诱导的肝葡萄糖生成。 p16〜(Ink4a)下调通过增加PKA调节亚基的磷酸化导致PKA-CREB-PGC1α信号的激活。综上所述,这些结果提供了p16〜(Ink4a)控制空腹血糖动态平衡的证据,并因此可能参与了T2D的发展。

著录项

  • 来源
    《Diabetes》 |2014年第10期|3199-3209|共11页
  • 作者单位

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

    Universite Lille 2, Lille, France,INSERM, U1011, Lille, France,European Genomic Institute for Diabetes, Lille, France,Institut Pasteur de Lille, Lille, France;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号